Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24670944 | 0.85 | NPC1 (0.52) | NPC1ALDH1A1RXFP1RAB9AKCNQ3 | |
| SCHEMBL25366886 | 0.77 | NPC1 (0.49) | NPC1ALDH1A1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL31241045 | 0.76 | KCNQ3 (0.53) | KDM4EP4HTMRAB9AKCNQ3KCNQ2 | |
| SCHEMBL760353 | 0.76 | NPC1 (0.48) | NPC1ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL6936745 | 0.75 | BACE1 (0.53) | NPC1ALDH1A1KDM4EP4HTMRAB9A | |
| SCHEMBL17593229 | 0.74 | NPC1 (0.47) | NPC1ALDH1A1KDM4ERAB9ABACE1 | |
| SCHEMBL2890734 | 0.74 | KDM4E (0.68) | NPC1KDM4ERXFP1RAB9AKCNQ3 | |
| SCHEMBL18370193 | 0.74 | NPC1 (0.47) | NPC1ALDH1A1RAB9AABL1SMN1; SMN2 | |
| SCHEMBL27158183 | 0.73 | KCNQ3 (0.47) | ALDH1A1KDM4EP4HTMKCNQ3KCNQ2 | |
| SCHEMBL18979450 | 0.73 | PTGFR (0.44) | NPC1ALDH1A1RXFP1RAB9AKCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086966-B1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2086966-B1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| WO-2008059042-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | EIF2AK2, HAVCR2, GTF3C2 | NPC1 1898/4885ALDH1A1 860/4885KDM4E 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.